Beta thalassemia major () is one of the more prevalent hereditary diseases in the globe due to a deficiency of globin chains. It is associated with lipid abnormalities, electrolytes, and oxidative stress that can lead to potentially fatal complications. The current study included 100 patients diagnosed with in an age group of 2-18 years compared to 80 healthy subjects. The current study included evaluating Complete blood count (CBC), iron status, lipid profile, potassium, and magnesium. Also, Oxidative status represented by Superoxide dismutase (SOD), Catalase (CAT), and Nitric oxide (NO) were investigated. The finding of this study included a significant increase of triglycerdes (Tg), very low-density lipoprotin (VLDL), and Potassium levels of the patients with compared to the healthy control group, while a significant decrease in total cholsterol (TC), high-density lipoprotin (HDL), low-density, lipoprotin (LDL), SOD, CAT, NO, and magnesium levels. Moreover, Pearson's correlation coefficient (r) was also found between the oxidative status parameters, Potassium, and magnesium studied for β-thalassemia patients vs ferritin levels that were found a negative correlation with SOD, CAT, NO, and magnesium levels whereas positive correlation with Potassium level. The finding of the current study showed a clinical predictor of dyslipidemia, state of oxidative stress, and high risk each of Hyperkalemia and hypomagnesemia, which portends the use of more efficient treatment protocols to remove excess iron from patients.


[1] Wang W-J, Ding Z-X, Zhang H-M, Tao T-T, Chen S-N, Xi L. Identification of a novel b-thalassemia mutation at codon 130 (þ T)(HBB: c. 391 insT) in han Chinese. Hemoglobin 2021; 45(1):46e8. https://doi.org/10.1080/03630269.2020.1862183.

[2] Costa E, Cappellini MD, Rivella S, Chilin A, Alessi E, Riccaboni M, et al. Emergent treatments for b-thalassemia and orphan drug legislations. Drug Discov Today 2022: 103342. https://doi.org/10.1016/j.drudis.2022.103342.

[3] Basu A, Chowdhury PK, Chowdhuy T, Sadhukhan S, Chakrabarti PK, Saha D, et al. Burdwan university thalassemia severity (BUTS) scoring system: a numerical method for defining the clinicopathological status of thalassaemia patient. 05. 01.21256431 medRxiv 2021;2021. https://doi.org/ 10.1101/2021.05.01.21256431.

[4] Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of b-thalassemia. Eur J Haematol 2020;105(6):692e703. https://doi.org/10.1111/ejh.13512.

[5] Abd HM, Al Samarrai OR, editors. Evaluation of hepcidin, ferritin and iron levels with liver enzymes of b-thalassemia patients in Diyala governorate, Iraq. AIP Conference Proceedings. AIP Publishing; 2022. https://doi.org/10.1063/ 5.0096262.

[6] Elalfy MS, Ebeid FS, El Gendy YG, Zaki MM, Kalifa AS. Body composition in Egyptian children with transfusion-dependent thalassemia: the impact of nutrition and metabolic profile. J Pediatr Hematol Oncol 2020;42(5):e334e9. https:// doi.org/10.1097/MPH.0000000000001712.

[7] Elbahy SM, Ayad SH, Elsayed RA, Nawar E. Cognitive function assessment in paediatric patients with beta-thalassemia major. Egyptian J Hosp Med 2023;90(2):2634e42. https://doi.org/10.21608/ejhm.2023.286411.

[8] Munoz CJ, Pires IS, Jani V, Gopal S, Palmer AF, Cabrales P. Apohemoglobin-haptoglobin complex alleviates iron toxicity in mice with b-thalassemia via scavenging of cell-free hemoglobin and heme. Biomed Pharmacother 2022;156:113911. https://doi.org/10.1016/j.biopha.2022.113911.

[9] Yin M, Liu Y, Chen Y. Iron metabolism: an emerging therapeutic target underlying the anti-cancer effect of quercetin. Free Radic Res 2021;55(3):296e303. https://doi.org/10.1080/ 10715762.2021.1898604.

[10] Hernaningsih Y, Syafitri Y, Indrasari YN, Rahmawan PA, Andarsini MR, Lesmana I, et al. Analysis of common betathalassemia (b-Thalassemia) mutations in East java, Indonesia. Frontiers in Pediatrics 2022;10:925599. https:// doi.org/10.3389/fped.2022.925599.

[11] Thein SL. The molecular basis of b-thalassemia. Cold Spring Harbor perspectives in Medicine 2013;3(5):a011700. https:// doi.org/10.1101/cshperspect.a011700.

[12] Garabet L, Ghanima W, Monceyron Jonassen C, Skov V, Holst R, Mowinckel M-C, et al. Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. Platelets 2019; 30(2):206e12. https://doi.org/10.1080/09537104.2017.1394451.

[13] Makmettakul S, Tantiworawit A, Phrommintikul A, Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, et al. Cardiorenal syndrome in thalassemia patients. BMC Nephrol 2020;21(1):1e11. https://doi.org/10.1186/s12882-020-01990-8.

[14] jaber Ibrahim A, Dwesh HAW, Shahid RA. Evaluation of serum leptin levels in hypertensive men in Thi Qar City-Iraq (a comparative study). J Popul Thera Clini Pharmacol 2023; 30(3):54e62. https://doi.org/10.47750/jptcp.2023.30.03.007.

[15] Jabbar HK, Hassan MK, Al-Naama LM. Lipids profile in children and adolescents with b-thalassemia major. Hematology, Transfusion and Cell Therapy 2022. https://doi.org/ 10.1016/j.htct.2022.09.1277.

[16] Nandi S, Samanta S, Mondal T, Halder S. Study of lipid profile in b thalassemia major pediatric patients with multiple blood transfusion and its correlation with serum ferritin level in tertiary care hospital in Kolkata. Int J Commu Med Public Health 2021;8(4):1778. https://doi.org/10.18203/2394- 6040.ijcmph20211233.

[17] Abdul-RedhaIsmaiel M. Relationship between oxidative stress and the blood iron concentration and antioxidant status in major ß-thalassemia in Iraq. Archives of Razi Institute 2022; 77(1):187. https://doi.org/10.22092/ARI.2021.356536.1863.

[18] Fibach E, Dana M. Oxidative stress in b-thalassemia. Mol Diagn Ther 2019;23:245e61. https://doi.org/10.1007/s40291- 018-0373-5.

[19] Tamer A, Aliaa AI, Abd EL-Hameed AH, Ebaa H. The oxidant and antioxidant status in b-thalassemia major patients. Med J Cairo Univ 2018;86(March):367e74. https:// doi.org/10.21608/mjcu.2018.55135.

[20] Abdulla AA. Evaluation of serum antioxidant enzymes in bthalassemia major patients. Int J ChemTech Res 2018;11(7): 323e8. https://doi.org/10.20902/IJCTR.2018.110738. Fig. 4. The Pearson correlation coefficient (r) among ferritin levels with magnesium levels in patients with b TM. 114 MA'AEN JOURNAL FOR MEDICAL SCIENCES 2023;2:108e115

[21] Alwataify ASM, Alshammary HN, Mahdi AH. Portal vein thrombosis in patients with b-thalassemia. The erythrocyteA unique cell. IntechOpen; 2022. https://doi.org/10.5772/ intechopen.106564.

[22] Tzounakas VL, Anastasiadi AT, Stefanoni D, Cendali F, Bertolone L, Gamboni F, et al. Beta thalassemia minor is a beneficial determinant of red blood cell storage lesion. Haematologica 2022;107(1):112. https://doi.org/10.3324/ haematol.2020.273946.

[23] Bhowad S, Samant P, Seth B. Biochemical assessment of renal function and its correlation with iron overloading in different variants of thalassemia. J Applied and Natural Science 2022; 14(3):1016e21. https://doi.org/10.31018/jans.v14i3.3718.

[24] Shmukler BE, Rivera A, Bhargava P, Nishimura K, Kim EH, Hsu A, et al. Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermedia. Blood Cell Mol Dis 2020;81:102389. https://doi.org/10.1016/j.bcmd.2019.102389.

[25] Munira FT, Begum S, Urmi S. Alteration of serum calcium and magnesium level in transfusion dependent thalassemic patients with combined iron chelator therapy. J Bangladesh Soc Physiol 2020;15(1):17e22. https://doi.org/10.3329/jbsp. v15i1.48111.